MedTrace Logo

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of PRV-3279 in Healthy Subjects

NCT03955666 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2023-08-28

No results posted yet for this study

Summary

This Phase 1b study will evaluate the safety of PRV-3279 in healthy adult subjects

Conditions

  • Safety

Interventions

BIOLOGICAL

PRV-3279 or placebo

bi-specific antibody-based molecule

Sponsors & Collaborators

  • Provention Bio, Inc.

    lead INDUSTRY

Principal Investigators

  • Chief Medical Officer · Provention Bio, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-08-07
Primary Completion
2019-12-11
Completion
2019-12-11
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03955666 on ClinicalTrials.gov